PLK4 and ovarian carcinoma: Targeting PLK4 with the small molecule inhibitor YLZ-F5 prevents human ovarian cancer growth by inducing aneuploidy and promotes apoptosis via activation of caspases-3/9 and impairs cell migration [304].